Deflazacort - Generic Drug Details

What are the generic drug sources for deflazacort and what is the scope of patent protection?

Deflazacort is the generic ingredient in two branded drugs marketed by Tris Pharma Inc, Ptc Therap, Aurobindo Pharma Ltd, and Upsher Smith Labs, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for deflazacort. Three suppliers are listed for this compound.

Summary for deflazacort

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	5
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	75
Clinical Trials:	23
Patent Applications:	6,857
What excipients (inactive ingredients) are in deflazacort?	deflazacort excipients list
DailyMed Link:	deflazacort at DailyMed

Recent Clinical Trials for deflazacort

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Parc de Salut Mar	Phase 1
FibroGen	Phase 3
Catabasis Pharmaceuticals	Phase 1

See all deflazacort clinical trials

Pharmacology for deflazacort

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for deflazacort

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for deflazacort

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	DEFLAZACORT	deflazacort	TABLET;ORAL	217123-003	Feb 9, 2024	AB	RX	No	No
Ptc Therap	EMFLAZA	deflazacort	TABLET;ORAL	208684-001	Feb 9, 2017	AB	RX	Yes	No
Ptc Therap	EMFLAZA	deflazacort	TABLET;ORAL	208684-004	Feb 9, 2017	AB	RX	Yes	Yes
Ptc Therap	EMFLAZA	deflazacort	TABLET;ORAL	208684-002	Feb 9, 2017	AB	RX	Yes	No
Ptc Therap	EMFLAZA	deflazacort	SUSPENSION;ORAL	208685-001	Feb 9, 2017	AB	RX	Yes	Yes
Ptc Therap	EMFLAZA	deflazacort	SUSPENSION;ORAL	208685-001	Feb 9, 2017	AB	RX	Yes	Yes

Deflazacort Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Deflazacort

Introduction to Deflazacort

Deflazacort, marketed under the brand name EMFLAZA, is a corticosteroid used primarily for the treatment of Duchenne muscular dystrophy (DMD) in patients five years of age and older. Here, we delve into the market dynamics and financial trajectory of this drug.

Market Size and Growth

The global deflazacort market has been experiencing significant growth. As of 2023, the market size was substantial, and it is projected to continue growing at a notable compound annual growth rate (CAGR) from 2024 to 2031[1][4].

Segmentation and Key Segments

The deflazacort market is segmented based on type and application. The suspension segment accounted for a noticeable share of the global market in 2023 and is expected to experience significant growth in the near future. The hospital segment is another key area, expected to expand at a significant CAGR throughout the forecast period[1].

Regional Analysis

The market is geographically segmented into five major regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Each region provides detailed insights into revenue share, current trends, and future prospects. North America, particularly the United States, is a significant market due to the FDA approval of EMFLAZA in 2017[1][4].

Key Players and Competitive Landscape

Companies like Sanofi and PTC Therapeutics are major players in the deflazacort market. PTC Therapeutics acquired the rights to EMFLAZA from Marathon Pharmaceuticals and has been focusing on commercializing the drug in the United States. These companies are strategizing to strengthen their product portfolios and expand their business globally[1][3].

Financial Performance and Revenue

PTC Therapeutics began recognizing revenue from EMFLAZA sales in the United States in May 2017. The revenue generated from EMFLAZA, along with other products like Translarna, has been crucial for the company's financial stability. The company relies on net sales of these drugs, as well as funding from clinical trials, grants, and patient advocacy groups[3].

Commercialization and Distribution

The commercialization of EMFLAZA involves third-party logistics companies for warehousing and specialty pharmacies for distribution. This strategy helps in optimizing distribution channels and ensuring timely delivery of the drug to patients. The company also focuses on negotiating adequate pricing, coverage, and reimbursement terms with third-party payors[3].

Regulatory and Market Exclusivity

EMFLAZA received FDA approval in February 2017 under the Orphan Drug Act, which provides market exclusivity for a certain period. This exclusivity is crucial for the company's revenue generation and competitive advantage. However, the company must also comply with FDA post-marketing requirements to maintain the marketing authorization[3].

Challenges and Opportunities

Despite the growth potential, the deflazacort market faces challenges such as the high cost of the drug, which can impact its long-term value. Studies have indicated that deflazacort and other similar treatments may represent low long-term value for the money spent[2].

On the other hand, the increasing awareness and diagnosis of DMD, along with advancements in healthcare infrastructure, present significant opportunities for market expansion. The demand for effective treatments for rare diseases like DMD is driving the growth of the deflazacort market[1][4].

Technological and Manufacturing Trends

The manufacturing process of deflazacort involves exclusive supply agreements, ensuring a stable supply chain. The report on the deflazacort market also provides insights into the complete manufacturing process and the major raw materials required, helping companies make informed decisions about product positioning and market opportunities[1].

Consumer Behavior and Market Trends

Consumer behavior analysis indicates a growing preference for effective treatments for rare diseases. The market trends are influenced by factors such as profit, product price, capacity, production, and supply-demand dynamics. These trends help in understanding the future prospects of the deflazacort market[1].

ESG, PESTEL, and SWOT Analysis

The market report includes detailed analyses such as ESG (Environmental, Social, and Governance), PESTEL (Political, Economic, Social, Technological, Environmental, and Legal), and SWOT (Strengths, Weaknesses, Opportunities, and Threats) analyses. These analyses provide a comprehensive understanding of the market's current state and future directions[1].

COVID-19 Impact

The COVID-19 pandemic has had various impacts on the pharmaceutical industry, including disruptions in supply chains and changes in consumer behavior. The deflazacort market has also been affected, but the demand for essential treatments like EMFLAZA has remained relatively stable[1].

Key Takeaways

• Market Growth: The global deflazacort market is projected to grow significantly from 2024 to 2031.
• Segmentation: The market is segmented by type (e.g., suspension) and application (e.g., hospitals), with the suspension segment and hospital segment being key areas.
• Regional Analysis: North America, particularly the United States, is a significant market due to FDA approval.
• Key Players: Companies like Sanofi and PTC Therapeutics are major players, with PTC Therapeutics focusing on commercializing EMFLAZA.
• Financial Performance: Revenue from EMFLAZA sales is crucial for companies like PTC Therapeutics.
• Challenges and Opportunities: High drug costs are a challenge, but increasing awareness and advancements in healthcare present opportunities.

FAQs

What is deflazacort used for?

Deflazacort, marketed as EMFLAZA, is used primarily for the treatment of Duchenne muscular dystrophy (DMD) in patients five years of age and older.

Who are the major players in the deflazacort market?

Major players include Sanofi and PTC Therapeutics, with PTC Therapeutics being a key player due to its acquisition of EMFLAZA from Marathon Pharmaceuticals.

What is the projected growth rate of the deflazacort market?

The global deflazacort market is projected to grow at a significant compound annual growth rate (CAGR) from 2024 to 2031.

How is EMFLAZA distributed?

EMFLAZA is distributed through third-party logistics companies for warehousing and specialty pharmacies for sales and distribution to patients.

What regulatory approvals has EMFLAZA received?

EMFLAZA received FDA approval in February 2017 under the Orphan Drug Act, providing market exclusivity for a certain period.

What are the challenges faced by the deflazacort market?

One of the significant challenges is the high cost of the drug, which can impact its long-term value for patients.

Sources

1. Global Deflazacort Market Report 2024 Edition - Cognitivemarketresearch.com
2. The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies - Jmcp.org
3. United States Securities and Exchange Commission - Ir.ptcbio.com
4. Deflazacort Market Global Demand, Opportunities, Trends, Analysis and Forecast to 2032 - Rivercountry.newschannelnebraska.com
5. DEFLAZACORT (EMFLAZA™)-REVISED - Dhcs.ca.gov